Pronounced “soh-TIK-too,” SOTYKTU is a once-daily pill for adults with moderate to severe plaque psoriasis that works inside ...

Psoriasis is a chronic, inflammatory skin condition, of which there are several types. Knowing what type of psoriasis you have can help you and your doctor come up with an effective treatment plan.

Using an existing steroid-free topical foam daily significantly improved the signs ... psoriasis. The condition causes the immune system to go into overdrive, resulting in the characteristic ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

66% of patients with scalp psoriasis ... the first targeted oral peptide designed to selectively block the IL-23 receptor, which underpins the inflammatory response in moderate-to-severe plaque ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...

Using social media as a pharma brand can feel risky due to regulatory constraints - but it can make a big impact when used in ...

Saviynt, a leading provider of cloud-native identity and governance platform solutions, continues to scale its global upskilling initiative through Saviynt University. In Sydney and Melbourne, Saviynt ...

Sunshine may hold healing rays for a variety of autoimmune diseases such as multiple sclerosis. Scientists are turning this ...

be sure the skin in that area is free of any plaques, scales, redness, or other signs of inflammation or irritation. “The most important thing is to try not to have psoriasis there,” says ...